Nathelia Bim
Adult Health · Anaheim, CANPI 1598245979
Payments from drug & device makers
Across 50 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$297
- Novo Nordisk$174
- Boehringer Ingelheim$123
- Lilly USA, LLC$57
- Hologic Sales And Service, LLC$49
- Otsuka America Pharmaceutical, Inc.$48
- plus $425 from 16 others
What the payments were for
- Food & beverage$1,175100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $297 |
| Novo Nordisk | 8 | $174 |
| Boehringer Ingelheim | 5 | $123 |
| Lilly USA, LLC | 2 | $57 |
| Hologic Sales And Service, LLC | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| GSK | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| Merck | 2 | $43 |
| Exact Sciences | 1 | $30 |
| Phadia US Inc. | 1 | $30 |
| Johnson & Johnson | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Pfizer | 1 | $17 |
| Indivior Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$121
How this compares
$1,175 in reported general payments places this provider in the 70th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $17,435 |
| JardianceEmpagliflozin | 16 | $9,168 |
| JanuviaSitagliptin Phosphate | 12 | $6,614 |
| VascepaIcosapent Ethyl | 14 | $5,407 |
| Icosapent Ethyl | 15 | $1,140 |
| Atorvastatin Calcium | 167 | $863 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $798 |
| Losartan Potassium | 46 | $363 |
| Telmisartan | 14 | $331 |
| Metformin Hcl | 37 | $259 |
| Metoprolol Succinate | 24 | $209 |
| Levothyroxine Sodium | 22 | $198 |
| Lisinopril | 48 | $162 |
| Amlodipine Besylate | 45 | $130 |
| Glipizide | 14 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $174 | $17,43517 claims |
| Boehringer IngelheimJardiance | $123 | $9,16816 claims |
| MerckJanuvia | $43 | $6,61412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 785 adult health providers in California.
Other adult health in Anaheim
- Naomi PesynaAnaheim$141K
- Karolina FaysmanLos Angeles$1.1M
- Siok-Hian Tay-KelleyStanford$611K
- Linda BuckLos Angeles$170K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.